Zydus Lifesciences’ US generics division -- Zydus Pharmaceuticals (USA) Inc is recalling 3,144 bottles of chlorproMAZINE Hydrochloride Tablets, USP 10 mg, a medication used to treat mental health conditions, like schizophrenia and bipolar disorder. The drug firm is recalling the affected lot due to CGMP deviations. There was ‘presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit’. The company initiated the Class II recall on April 3, 2025.
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
